mAbxience S.L.
http://www.mabxience.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From mAbxience S.L.
Intas And mAbxience Strike Global Etanercept Deal
Intas and mAbxience have announced an exclusive licensing agreement covering mAbxience’s etanercept biosimilar candidate in more than 150 countries worldwide, including Europe and the US.
Turkey’s Abdi İbrahim Allies With mAbxience For ‘Unprecedented’ Technology Transfer
Five years after striking a biosimilars alliance with Iceland’s Alvotech, Turkish firm Abdi İbrahim – which boasts the country’s “largest biotech pharmaceutical manufacturing facility” – has shaken hands with Spanish developer mAbxience for technology transfer of an undisclosed oncology biosimilar.
Another Denosumab Deal For mAbxience In MEA
A further licensing deal for biosimilar denosumab has been struck by mAbxience, with MS Pharma set to register and market the Prolia/Xgeva rival in “select MEA markets.”
Amneal Posts Second Guidance Raise Of The Year Ahead Of Q3 Earnings Report
Amneal has raised its 2023 guidance yet again as company performance remained strong across Q3.
Company Information
- Industry
- Services
- Contract Manufacturing Organization
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- CHEMO Group
- Kevilmare Holding GmbH
- Insud Pharma
- mAbxience S.A
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice